Literature DB >> 2122604

Prophylaxis of venous thromboembolism.

V V Kakkar1, M D Stringer.   

Abstract

The objective of prophylaxis in venous thromboembolism is, first, to prevent fatal pulmonary embolism and, second, to reduce the morbidity associated with deep vein thrombosis (DVT) and the postphlebitic limb. This should now be standard practice for most patients over 40 years of age undergoing major surgery and for younger patients with a history of venous thromboembolism. Particularly high-risk groups include patients over 60 years of age undergoing major surgery, those with malignancy, and those requiring hip operations. Low-dose subcutaneous heparin 5,000 IU commencing 2 hours preoperatively and continuing 12 hourly until the patient is fully mobile is unequivocally effective in preventing DVT in medical and surgical patients and, most importantly, significantly reduces the incidence of fatal postoperative pulmonary embolism and total mortality. Such prophylaxis, in the presence of established DVT, also limits proximal clot propagation, which is the precursor of major pulmonary embolism. Low-dose heparin prophylaxis is associated with a small risk of bleeding complications, evidenced mostly by an increased frequency of wound hematoma rather than major clinical hemorrhage. Low molecular weight heparin fragments (e.g., Fragmin, Choay, Enoxaparine) are emerging as useful alternative agents, having the advantage of once daily administration and yet providing similar efficacy in the prevention of DVT. Mechanical methods of prevention which counteract venous stasis, such as graduated elastic compression stockings, are also useful in protecting against DVT but have not been shown to prevent fatal postoperative pulmonary embolism. They are recommended particularly for patients in whom heparin prophylaxis is best avoided (e.g., neurosurgery) and possibly in combination with heparin in very high-risk patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2122604     DOI: 10.1007/bf01658824

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  89 in total

1.  Efficacy and safety of two regimens of low molecular weight heparin fragment (Fragmin) in preventing postoperative venous thrombolism.

Authors:  V V Kakkar; S Kakkar; R M Sanderson; C E Peers
Journal:  Haemostasis       Date:  1986

2.  Proceedings: Low dose subcutaneous heparin--optimal dose regimen.

Authors:  T P Corrigan; V V Kakkar; D P Fossard
Journal:  Br J Surg       Date:  1974-04       Impact factor: 6.939

3.  Prevention of deep-vein thrombosis by low-dose heparin in patients undergoing total hip replacement.

Authors:  G K Morris; A P Henry; B J Preston
Journal:  Lancet       Date:  1974-10-05       Impact factor: 79.321

4.  Efficacy and safety of low-molecular-weight heparin (CY216) in preventing postoperative venous thrombo-embolism: a co-operative study.

Authors:  V V Kakkar; W J Murray
Journal:  Br J Surg       Date:  1985-10       Impact factor: 6.939

5.  Dextran 70 in prophylaxis of thromboembolic disease after surgery: a clinically oriented randomized double-blind trial.

Authors:  A Kline; L E Hughes; H Campbell; A Williams; J Zlosnick; K G Leach
Journal:  Br Med J       Date:  1975-04-19

6.  Prevention of fatal postoperative thromboembolism by heparin prophylaxis.

Authors:  J G Sharnoff; G DeBlasio
Journal:  Lancet       Date:  1970-11-14       Impact factor: 79.321

7.  Deep vein thrombosis of the leg. Is there a "high risk" group?

Authors:  V V Kakkar; C T Howe; A N Nicolaides; J T Renney; M B Clarke
Journal:  Am J Surg       Date:  1970-10       Impact factor: 2.565

8.  A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery.

Authors:  A G Turpie; M N Levine; J Hirsh; C J Carter; R M Jay; P J Powers; M Andrew; R D Hull; M Gent
Journal:  N Engl J Med       Date:  1986-10-09       Impact factor: 91.245

9.  Four heparin preparations: anti-Xa potentiating effect of heparin after subcutaneous injection.

Authors:  E A Johnson; T B Kirkwood; Y Stirling; J L Perez-Requejo; G I Ingram; D R Bangham; M Brozović
Journal:  Thromb Haemost       Date:  1976-06-30       Impact factor: 5.249

10.  Graded compression for preventing deep venous thrombosis.

Authors:  C P Holford
Journal:  Br Med J       Date:  1976-10-23
View more
  6 in total

1.  Deep venous thrombosis and pulmonary embolism are uncommon in East Asian patients after total hip arthroplasty.

Authors:  Bun Jung Kang; Young-Kyun Lee; Hee Joong Kim; Yong-Chan Ha; Kyung-Hoi Koo
Journal:  Clin Orthop Relat Res       Date:  2011-07-12       Impact factor: 4.176

2.  Prospective randomized clinical study in general surgery comparing a new low molecular weight heparin with unfractionated heparin in the prevention of thrombosis.

Authors:  J Limmer; D Ellbrück; H Müller; E Eisele; J Rist; F Schütze; H Beger; H Heimpel; E Seifried
Journal:  Clin Investig       Date:  1994-11

3.  Postoperative nadroparin administration for prophylaxis of thromboembolic events is not associated with an increased risk of hemorrhage after spinal surgery.

Authors:  Rüdiger Gerlach; Andreas Raabe; Jürgen Beck; Alina Woszczyk; Volker Seifert
Journal:  Eur Spine J       Date:  2003-11-13       Impact factor: 3.134

Review 4.  Prophylaxis of venous thromboembolism in brain tumor patients.

Authors:  M G Hamilton; R D Hull; G F Pineo
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

5.  Little impact of antiplatelet agents on venous thromboembolism after hip fracture surgery.

Authors:  Hyung-Min Ji; Young-Kyun Lee; Yong-Chan Ha; Ki-Choul Kim; Kyung-Hoi Koo
Journal:  J Korean Med Sci       Date:  2011-11-29       Impact factor: 2.153

6.  Preventing Venous Thromboembolism with Use of Intermittent Pneumatic Compression after Total Hip Arthroplasty in Korean Patients.

Authors:  Woo-Lam Jo; Young-Kyun Lee; Yong-Chan Ha; Kyung-Min Lee; Bun-Jung Kang; Kyung-Hoi Koo
Journal:  J Korean Med Sci       Date:  2016-05-24       Impact factor: 2.153

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.